Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities—A Phase II Multi-center Randomised Controlled Trial

Trial Profile

Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities—A Phase II Multi-center Randomised Controlled Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Alprostadil (Primary)
  • Indications Arteriosclerosis obliterans
  • Focus Therapeutic Use
  • Sponsors Yipinhong Pharmaceutical
  • Most Recent Events

    • 08 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top